SCI-110 in the Treatment of Tourette Syndrome

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.

Phase 2

SciSparc